Research programme: autoimmune disorder therapeutics - IMTM GmbHAlternative Names: PETIR-001
Latest Information Update: 16 Jul 2016
At a glance
- Originator IMTM GmbH
- Mechanism of Action CD13 antigen inhibitors; CD26 antigen inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (Intraperitoneal)
- 01 Mar 2011 Preclinical trials in Multiple sclerosis in Germany (Intraperitoneal)